Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent liver diseases worldwide. The underlying causes involve obesity and decreased physical activity leading to accompanying metabolic and cardiovascular diseases. Currently no approved pharmacotherapy is available. Therefore, the aim of a new joint research initiative is to employ a novel and applicable lifestyle intervention that is feasible and exerts a lasting benefit.